Results 71 to 80 of about 1,626,261 (197)
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy.
Igor Rubinić +2 more
doaj +1 more source
ABSTRACT Introduction Although GLP‐1‐based pharmacotherapies achieve clinically significant weight loss, their influence on eating behavior is unknown. Methods This systematic review examined the effects of GLP‐1‐based pharmacotherapies on eating behavior, appetite, and energy intake in adults (≥ 18 years) with overweight or obesity (BMI ≥ 25 kg/m2 ...
Clarissa Dakin +2 more
wiley +1 more source
Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity
Obesity is a chronic, multifactorial disease with escalating global prevalence, associated with profound metabolic, cardiovascular, and oncological comorbidities.
Marcelina Rybińska +3 more
doaj +1 more source
GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
ABSTRACT Obesity is a well‐established risk factor for numerous cancers, with body habitus, especially central adiposity, contributing to increased cancer incidence and worse prognosis. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed to treat Type 2 diabetes, have rapidly gained prominence as powerful anti‐obesity agents due ...
Lorne J. Hofseth +6 more
wiley +1 more source
CGRP Receptor Family and Accessory Protein Localization: Implications for Predicted Function
Calcitonin gene-related peptide (CGRP), adrenomedullin, amylin, and calcitonin are functionally related neuropeptides. Certain of these peptides mediate their action through receptors which have common components, such as the receptor activity modifying ...
K.R. Oliver
doaj +1 more source
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet +2 more
wiley +1 more source
Recent findings revealed that type 2 diabetes mellitus (T2D) is a chronic inflammatory disease and an islet amyloid polypeptide (IAPP)/amylin, is deposited within pancreatic islets.
Shinnosuke Morikawa +9 more
doaj +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj +1 more source
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
ABSTRACT Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking ...
Osman Corbali +4 more
wiley +1 more source

